Liver Cirrhosis Epidemiology

Liver Cirrhosis Insights and Trends

• Liver cirrhosis is a chronic progressive disease caused by various liver injury mechanisms, characterized by irreversible fibrosis, hepatocyte degeneration and necrosis, and the formation of regenerative nodules, ultimately leading to liver failure and multiple severe complications, significantly increasing the risk of mortality.
• DelveInsight's analysis indicates that there were over 3 million diagnosed prevalent cases of liver cirrhosis across the 7MM in 2025. The United States contributed the largest proportion of these cases, underscoring its significant epidemiological burden within the major markets.
• According to DelveInsight, EU4 and the UK collectively accounted for 24% of the total diagnosed prevalent liver cirrhosis cases across the 7MM in 2025. The patient population in these markets is projected to increase steadily over the forecast period (2026–2036). 
• The diagnosis of liver cirrhosis is based on a combination of clinical evaluation, laboratory investigations, imaging studies, and, when necessary, liver biopsy. Initial assessment includes a detailed medical history and physical examination, along with liver function tests, complete blood count, coagulation profile, and serum albumin levels to evaluate hepatic function and identify complications.
• The increasing burden of liver cirrhosis may be attributed to a combination of factors, including the growing prevalence of obesity, diabetes, metabolic syndrome, excessive alcohol consumption, chronic hepatitis B and C infections, aging populations, and improved survival of patients with chronic liver disease, resulting in a larger pool of individuals progressing to cirrhosis.

DelveInsight’s “Liver Cirrhosis Epidemiology, Forecast – 2036” report delivers an in depth understanding of liver cirrhosis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

North America: The United States 

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Liver Cirrhosis Understanding 

Liver Cirrhosis Overview and Diagnosis

Cirrhosis is the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, leading to portal hypertension and end-stage liver disease. In this late-stage liver disease, the healthy liver tissue is replaced with scar tissue, and the liver is permanently damaged, and scar tissue keeps the liver from working properly. Cirrhosis has many signs and symptoms, such as fatigue and severe itchy skin, and they may not appear until the liver is badly damaged. Causes include alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B.

Most patients with early-stage cirrhosis are asymptomatic, and the disease is often detected incidentally through routine blood tests or imaging. Although liver biopsy remains the gold standard for confirming cirrhosis, it is an invasive procedure that many patients find uncomfortable. As symptoms such as jaundice appear only in advanced, irreversible stages, opportunities for early intervention are often missed. Current diagnostic approaches, including imaging and liver function tests, have limited sensitivity for detecting early disease and predicting progression, highlighting the need for more accurate, reliable, and non-invasive biomarkers for early diagnosis and disease monitoring.

Further details related to country-based variations are provided in the report…

Liver Cirrhosis Epidemiology

Key Findings from Liver Cirrhosis Epidemiological Analysis and Forecast

• The US showed the highest diagnosed prevalent population of liver cirrhosis compared to the other 7MM countries, with more than 2 million cases in 2025. As per DelveInsight’s estimates, the country alone accounts for nearly 61% of total diagnosed prevalent cases, for liver cirrhosis in the 7MM, followed by Japan, contributing 15% of all the liver cirrhosis cases.
• The etiology-specific distribution of diagnosed prevalent cases of liver cirrhosis showed NASH, HCV, HVB, ALD, and PBC comprised 28%, 27%, 11%, 33%, and 2% cases, respectively in the 7MM in 2025.
• EU4 and the UK accounted for approximately 1 million diagnosed prevalent cases of liver cirrhosis in 2025. Of these cases, Germany accounted for the highest number of diagnosed prevalent cases of liver cirrhosis between EU4 and the UK.
• Japan accounted for more than 500,000 cases of the total diagnosed prevalent cases of liver cirrhosis in the 7MM in 2025.

Industry Experts and Physician Views for liver cirrhosis

To keep up with liver cirrhosis dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the liver cirrhosis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Center such as Duke University School of Medicine, University of Florida Gainesville, Stanford University, Liver Unit, Hospital Clinic of Barcelona, Iwate Medical University, Leipzig University Hospital, and University of Florida etc. were contacted. 

Their opinion helps understand, validate, highlight and provide epidemiological context in liver cirrhosis.

Note: Detailed assessment of KOL Views will be provided in the full report on liver cirrhosis

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of liver cirrhosis, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Liver cirrhosis Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 

FAQs

• What are the disease risks, burdens, and unmet needs of liver cirrhosis? 
• What will be the growth opportunities across the 7MM concerning the patient population with liver cirrhosis?
• What is the liver cirrhosis prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted liver cirrhosis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on liver cirrhosis burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the liver cirrhosis epidemiology analysis and patient population trends.